Navigation Links
BioRestorative Therapies Announces Stock Trading On OTC Bulletin Board
Date:11/5/2012

JUPITER, Fla., Nov. 5, 2012 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on stem cell based cellular therapies for various personal medical applications, announced today that its common stock has begun trading on the OTC Bulletin Board.

Mark Weinreb, Chief Executive Officer of BRT, commented on the up listing, "We went through a very thorough and diligent review process by FINRA to attain the Bulletin Board listing.  The Bulletin Board trading platform allows for more potential investors interested in purchasing our stock. We are extremely pleased to provide investors increased visibility and transparency that this regulated quotation service provides so the Company can continue the pursuit of its goal of becoming a leader in developing ground-breaking medical procedures."

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT") develops medical procedures using cell and tissue protocols, primarily involving adult stem cells (non-embryonic), and allowing patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives: Our brtxDISC™ Program (Disc Implanted Stem Cells) offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures.  

Our ThermoStem™Program focuses on treatments for metabolic disorders (diabetes, heart disease, etc.) and obesity and uses brown fat stem cells. Initial research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body. The Company also offers plant stem cell-based facial creams and products under the Stem Pearls® brand at
'/>"/>

SOURCE BioRestorative Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
2. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
3. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
4. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
5. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
6. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
7. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
8. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
9. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
10. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
11. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical ... presentations at three investor conferences: , Wednesday, September ... in New York at the New ... PM at the BioCentury NewsMakers Conference in New ... Center , Thursday, September 17 at 9:30 AM at ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form of macular ... anti-vascular endothelial growth factor agents given by injection into the eye. Dry macular ... scientific protocol for the many millions diagnosed with it. AMD usually starts in ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... botanical and plant-derived compounds. BCC Research reveals in its new report that ... this market defines the category and generates the most market demand. , ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... N.C. and ROCKVILLE, M.D., June 5 ,Laboratory ... LH ), one,of the world,s leading clinical ... Inc. (Nasdaq: VNDA ), a biopharmaceutical ... clinical-stage product,candidates for central nervous system disorders, ...
... Results of phase I/II study highlighted in oral presentation at ... ... Switzerland, June 5 At the 10th,International Conference on Malignant ... investigator-sponsored clinical trial of,Yttrium-90 Ibritumomab Tiuxetan (90Y-Zevalin) combined with the ...
... 4 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... vice president of research and development, is scheduled ... Biotechnology & Medical Technology,Conference on June 12 at ... at the,New York Palace Hotel in New York ...
Cached Biology Technology:LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 2LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 3LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 4LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 5Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 2Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 3Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 4Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference 2
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... the human gut adaptively shifts more than a quarter ... diet changes from sugar to complex carbohydrates. , This ... survive rapidly changing nutrient conditions but also helps maintain ... microbial society, according to researchers at Washington University School ...
... Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced ... "Multiplexed Active Biologic Array" by the U.S. Patent and ... of addressing one or more electrodes (or "test sites") ... patent also covers a method for storing the value ...
... owners because of their vibrant colors. But those colors may ... For more than a century, biochemists have known that parrots ... of plumage colors, but their biochemical identity has remained elusive. ... behind the colors of parrots, describing on a molecular level ...
Cached Biology News:Highly adaptable genome in gut bacterium key to intestinal health 2Highly adaptable genome in gut bacterium key to intestinal health 3Nanogen Issued Patent for Electronic Microarray With Memory 2Transport System Smuggles Medicines Into Brain 2Transport System Smuggles Medicines Into Brain 3
... provides high-pressure tubing for use with ... chromatography systems. The kit includes precut ... PEEK tubing for the installation of ... running at flow rates less than ...
... 96 x 0.2 ml tubes or a ... a thumbwheel to adjust height and pressure ... cycling. Peltier heat pumps produce uniform, accurate ... of up to 1.4 degrees C per ...
... thermocycler provides maximum performance on minimum space. ... elements, high heating and cooling rates have ... times. With a maximum capacity of 48 ... the capacity of much more expensive 96 ...
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
Biology Products: